Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Vredevoogd

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Cell Reports. Medicine|June 10, 2022
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cellsZhengkui Zhang, Xiangjun Kong, Maarten A Ligtenberg, et al.
Cancer Research|February 3, 2021
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint BlockadeJulia Boshuizen, Nora Pencheva, Oscar Krijgsman, et al.
Nature Communications|April 9, 2022
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signalingGeorgi Apriamashvili, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Cell|January 25, 2020
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, et al.
Nature Medicine|January 16, 2018
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitorsJulia Boshuizen, Louise A Koopman, Oscar Krijgsman, et al.
Cell Reports. Medicine|February 22, 2023
An adverse tumor-protective effect of IDO1 inhibitionJuliana C N Kenski, Xinyao Huang, David W Vredevoogd, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cell Reports. Medicine|June 10, 2022
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cellsZhengkui Zhang, Xiangjun Kong, Maarten A Ligtenberg, et al.
Cancer Research|February 3, 2021
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint BlockadeJulia Boshuizen, Nora Pencheva, Oscar Krijgsman, et al.
Nature Communications|April 9, 2022
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signalingGeorgi Apriamashvili, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Cell|January 25, 2020
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, et al.
Nature Medicine|January 16, 2018
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitorsJulia Boshuizen, Louise A Koopman, Oscar Krijgsman, et al.
Cell Reports. Medicine|February 22, 2023
An adverse tumor-protective effect of IDO1 inhibitionJuliana C N Kenski, Xinyao Huang, David W Vredevoogd, et al.
Pageof 3